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Amyloid-β peptide deposition, abnormal hyperphosphorylation of tau, as well as inﬂam-
mation and vascular damage, are associated with the development of Alzheimer’s disease
(AD). Angiotensin II (Ang II) is a peripheral hormone, as well as a neuropeptide, which binds
two major receptors, namely the Ang II type 1 receptor (AT1R) and the type 2 receptor
(AT2R). Activation of the AT2R counteracts most of the AT1R-mediated actions, promoting
vasodilation, decreasing the expression of pro-inﬂammatory cytokines, both in the brain and
in the cardiovascular system.There is evidence that treatment with AT1R blockers (ARBs)
attenuates learning and memory deﬁcits. Studies suggest that the therapeutic effects of
ARBs may reﬂect this unopposed activation of the AT2R in addition to the inhibition of
the AT1R. Within the context of AD, modulation of AT2R signaling could improve cogni-
tive performance not only through its action on blood ﬂow/brain microcirculation but also
through more speciﬁc effects on neurons. This review summarizes the current state of
knowledge and potential therapeutic relevance of central actions of this enigmatic recep-
tor. In particular, we highlight the possibility that selective AT2R activation by non-peptide
and highly selective agonists, acting on neuronal plasticity, could represent new pharma-
cological tools that may help improve impaired cognitive performance in AD and other
neurological cognitive disorders.
Keywords: angiotensin II, angiotensin type 2 receptor, neuron, cognition, brain damage, vasodilation, Alzheimer’s
disease
INTRODUCTION
Angiotensin II (Ang II) is the active end-product of the renin–
angiotensin system (RAS). In the classical view,Ang II is produced
from angiotensinogen through a series of proteolytic cleavage
events, conducted successively by renin, followed by angiotensin-
converting enzyme (for review see de Gasparo et al., 2000; de Kloet
et al., 2010). However, in addition to this classical RAS, several
alternative pathways have been identiﬁed, for which description is
out of the scope of this review, but recently reviewed by de Kloet
et al. (2010) and Abassi et al. (2009). Ang II is a peripheral hor-
mone, as well as a neuropeptide, which plays a major role in the
central regulation of blood pressure and in the stress response.
Indeed, since the pioneer studies of Mendelsohn et al. (1988)
and Unger et al. (1988), the existence of a RAS in the brain is
now well established. The various components (angiotensinogen,
renin, angiotensin-converting enzyme, Ang II, and Ang II recep-
tors) are found in areas of the brain involved in the regulation of
ﬂuid and electrolyte balance, in the regulation of arterial pressure
and in structures involved in cognition, behavior, and locomotion
(for review see Phillips anddeOliveira,2008;Horiuchi et al., 2010).
Angiotensin II binds two major receptors: the Ang II type 1
receptor (AT1R) and the type 2 receptor (AT2R). Since Ang II
modulates blood pressure and the stress response by binding the
AT1R, AT1R blockers (ARBs) have been widely used as antihyper-
tensive drugs. There is also evidence thatARB treatment attenuates
learning and memory deﬁcits, increases cerebral blood ﬂow, and
helps protect against brain ischemia and inﬂammation (Li et al.,
2005; Zhou et al., 2006; Phillips and de Oliveira, 2008; Mogi and
Horiuchi, 2009; Sakata et al., 2009; Horiuchi et al., 2010). In the
presence of ARBs, which selectively block the AT1R, Ang II binds
to the less-abundant AT2R. Several studies suggest that the ther-
apeutic effects of ARBs may reﬂect this unopposed activation of
the AT2R as well as the inhibition of the AT1R (Li et al., 2007b;
Tsukuda et al., 2007, 2009; Arganaraz et al., 2008; Gao et al., 2008;
McCarthy et al., 2009).
Within the context of Alzheimer’s disease (AD), modulation
of AT2R signaling could improve cognitive performance not only
through its action on blood ﬂow/brain microcirculation but also
through more speciﬁc effects on neurons. This review summarizes
the current state of knowledge and potential therapeutic relevance
of central actions of this enigmatic receptor.
EXPRESSION AND ROLES OF THE AT2R IN THE BRAIN
One of the most striking features of the AT2R is its high level
of expression in most fetal tissues, including the brain, and
the dramatic increase in the AT1/AT2 receptor ratio after birth
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(Millan et al., 1991; Tsutsumi and Saavedra, 1991). This pattern
of expression strongly implicates the AT2R in fetal development.
In the adult, the AT2R is predominantly expressed in the locus
coeruleus, ventral and dorsal parts of lateral septum, superior col-
liculus and subthalamic nucleus, many nuclei of the thalamus,
and nuclei of the inferior olive. The cingulate cortex, the mol-
ecular layer of the cerebellar cortex, the superior colliculus and
paraventricular nuclei contain both AT1 and AT2 receptors (Mil-
lan et al., 1991; Tsutsumi and Saavedra, 1991; Lenkei et al., 1996,
1997). More recent studies have also identiﬁed AT2R RNA and
protein in the substantia nigra pars compacta (Grammatopou-
los et al., 2007) and in the hippocampus (Arganaraz et al., 2008;
Abdalla et al., 2009). Thus, in the adult, the AT2R are concentrated
in areas involved in control and learning of motor activity, sensory
areas, and selected limbic system structures. At the cellular level,
theAT2R is localized in neurons but not in astrocytes (Bottari et al.,
1992; Lenkei et al., 1996; Gendron et al., 2003b). It is well-accepted
that AT2R stimulation counteracts most AT1R-mediated actions,
promoting vasodilation, inhibiting growth, decreasing the expres-
sion of pro-inﬂammatory cytokines, and increasing expression of
anti-inﬂammatory cytokines, both in the brain and in the car-
diovascular system (for reviews see Gendron et al., 2003b; Mogi
et al., 2007a, 2008; Arganaraz et al., 2008; Mogi and Horiuchi,
2009; Porrello et al., 2009; Sakata et al., 2009; Tsukuda et al., 2009;
Figure 1).
IS THERE A LINK BETWEEN AT2R ACTIVATION AND AD?
Amyloid-β (Aβ) peptide deposition in senile plaques and the pres-
ence of neuroﬁbrillary tangles (NFTs) are the main pathological
hallmarks of AD. However, other structural and functional alter-
ations, including inﬂammation, increased oxidative stress, and
vascular damage/ischemia, are also associated with AD; these
alterations may contribute to neuronal and synaptic dysfunction
and loss as well as the ensuing cognitive deﬁcits and dementia
of this disorder (Iadecola, 2004; Zlokovic, 2005; LaFerla et al.,
2007; Boissonneault et al., 2009; Mucke, 2009; Nelson et al., 2009).
In addition, since the development of the amyloid hypothesis of
Hardy and Selkoe (2002), evidence strongly suggests that soluble
oligomers of Aβmay cause early cognitive impairment, even in the
absence of overt cell death (review in Mucke et al., 2000; Hardy
and Selkoe, 2002; Lesne et al., 2006;Haass and Selkoe, 2007; Selkoe,
2008; Wray and Noble, 2009).
The abnormal hyperphosphorylation and altered conforma-
tion of the microtubule-associated protein (MAP) tau precedes
its assembly into paired helical ﬁlaments and its accumulation in
NFTs (Buee et al., 2000; Andorfer et al., 2003; Gallo et al., 2007;
Hanger et al., 2009; Iqbal et al., 2009). Tau is a substrate for several
protein kinases, such as glycogen synthase kinase-3 (GSK-3) and
cyclin-dependent kinase (cdk5), and for phosphatases such as pro-
tein phosphatase-2A (PP2A); PP2A activity is down-regulated in
the AD brain (Buee et al., 2000; Andorfer et al., 2003; Gallo et al.,
2007; Hernandez and Avila, 2008; Hanger et al., 2009; Iqbal et al.,
2009; Hernández et al., 2010).
Moreover, experimental evidence suggests that cerebral perfu-
sion is decreased in AD (Farkas and Luiten, 2001; de la Torre,
2004; Zlokovic, 2008; Liu et al., 2009). Indeed, the structural and
functional integrity of the brain depends on the delicate bal-
ance between substrate delivery through blood ﬂow and energy
demands imposed by neural activity. Neurons, astrocytes and vas-
cular cells seemingly constitute a functional unit, the primary
purpose of which is to maintain the homeostasis of the brain’s
microenvironment. Alterations of these vascular regulatory mech-
anisms lead to brain dysfunction and disease. The emerging view
is that cerebrovascular dysregulation is a feature not only of
FIGURE 1 | Summary of the properties and main effects targeted by AT1 andAT2 receptors of angiotensin II in the brain.
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cerebrovascular pathologies such as stroke, but also of neurode-
generative conditions such as AD (Iadecola et al., 2009). Since
studies suggest that Aβ has deleterious actions both on neurons
and cerebral blood vessels, the neuronal and vascular actions of
this peptide may act synergistically to induce brain dysfunction in
AD (Iadecola, 2004; Zlokovic, 2005).
Recent studies have revealed that aging, hypertension, and
AD trigger common signaling pathways that lead to deleterious
effects on the regulation of the cerebral circulation. These ﬁndings
reinforce the notion that cerebrovascular dysfunction plays a key
role in the cognitive impairment associated with these conditions
(Iadecola et al., 2009). In the entire trademark dysfunctions asso-
ciated with AD mentioned above, there is several indirect lines
of evidence suggesting that AT2 receptor activation may have a
beneﬁcial effect (de la Torre, 2004).
All of the components of the RAS are found in the brain,
where they actively modulate functions such as stress (Saavedra
et al., 2005; Saavedra and Benicky, 2007), exploratory behav-
ior, anxiety, learning, and memory acquisition (Wright et al.,
2002; Phillips and de Oliveira, 2008). Both the AT1R and the
AT2R have been detected in brain areas responsible for these
functions, including the amygdala, hippocampus, lateral septum,
and frontal cortex (Song et al., 1991, 1992; Lenkei et al., 1996;
Phillips and Sumners, 1998; Arganaraz et al., 2008; Abdalla et al.,
2009). The initial studies indicating a role of AT2R in cognitive
improvement arise from observations in AT2R-deﬁcient mice.
The targeted disruption of the Agtr2 gene (which codes for the
AT2R) resulted not only in a signiﬁcant increase in blood pres-
sure, but also in attenuated exploratory behavior and impaired
performance in a spatial memory task (Hein et al., 1995; Ichiki
et al., 1995; Okuyama et al., 1999; Maul et al., 2008). Several recent
studies have indicated a beneﬁcial role for ARBs in the cogni-
tive impairment associated with vascular diseases, AD, and other
neurodegenerative diseases (Phillips and de Oliveira, 2008; Fujita
et al., 2009; Mogi and Horiuchi, 2009). For instance, treatment
with the ARB valsartan attenuates oligomerization of Aβ pep-
tides into high molecular weight oligomeric peptides and reduces
cognitive deterioration in Tg2576 mice, a model of AD-type neu-
ropathology that expresses a pathogenic mutant of the amyloid
precursor protein (APP; Wang et al., 2007). On the other hand,
other studies with the same model (Tg2576 mice) have shown
that Aβ induces the formation of cross-linked AT2R oligomers in
the hippocampus that disrupt Ang II signaling. This Aβ-induced
AT2R oligomerization was associated with enhanced neurodegen-
eration. Conversely, stereotactic inhibition of AT2R oligomers by
RNA interference delayed tau phosphorylation in Tg2576 (Abdalla
et al., 2009).
Numerous studies suggest that the beneﬁcial cellular effects of
the AT2R result in improved physiological parameters relevant to
AD patients:
• Ang II type 2 receptor activation promotes vasodilation and
the anti-inﬂammatory process –Considerable evidence suggests
that AT1R blockade and increased AT2R stimulation improve
cerebral blood ﬂow, thereby helping to protect against brain
ischemia and inﬂammation (Iwai et al., 2004; Li et al., 2005;
Zhou et al., 2006; Sakata et al., 2009), and, moreover, that
AT2R activation improves the microcirculation (for reviews,
see Phillips and de Oliveira, 2008; Horiuchi et al., 2010).
• Ang II type 2 receptor activation protects against brain dam-
age – Numerous recent studies conducted in rodents treated
withARBs suggest thatAT2Rprotects against cerebral ischemia-
induced neuronal injury (Grammatopoulos et al., 2004; Li et al.,
2005; Tsukuda et al., 2007, 2009; McCarthy et al., 2009), and
altered dendritic and neuronal spine morphology (Maul et al.,
2008; for review see Mogi and Horiuchi, 2009). Conﬁrming
these observations, it has been reported that AT2R stimulation
supports neuronal survival and neurite outgrowth in response
to ischemia-induced neuronal injury (Li et al., 2005; Sakata
et al., 2009). Further supporting a role of AT2R in neurite out-
growth are observations from models of nerve injury which
have elegantly shown that the AT2R has regenerative capabili-
ties associated with restored behavioral function and anatomic
innervation after sciatic nerve crush and optical axotomy (Gal-
linat et al., 1998; Lucius et al., 1998; Reinecke et al., 2003; Li
et al., 2005).
• Alzheimer’s disease and the neurotrophic hypothesis: a role for
AT2R? –As recently summarized by Schindowski et al. (2008),
neurotrophic factors [such as nerve growth factor (NGF) and
brain-derived neurotrophic factor] are key regulators not only
for development, maintenance and survival but also for cog-
nition and storage of memory. They activate various cell sig-
naling pathways acting through the tropomyosin-related kinase
or tyrosine receptor kinase family (Trk). Most neurodegener-
ative dementias are linked to failures in axonal transport of
neurotrophic factors from the cell body (where they are syn-
thesized) to their sites of action. For example, in the absence
of NGF, morphology and functions of cholinergic neurons are
impaired, resulting in a decrease in cholinergic transmission.
In this context, we have shown that AT2R-mediated effects
in vitro are modulated by the presence of growth factors in
the culture medium, and are mediated by growth factor-related
signaling pathways. In particular, the signaling mechanisms
leading to neurite outgrowth in NG108-15 cells involves the
TrkA-mediated activation of Rap1/B-Raf, which in turn, acti-
vates MEK to induce a delayed but sustained activation of
p42/p44mapk (Gendron et al., 2003a; Plouffe et al., 2006).
• Alzheimer’s disease as a consequence of hypertension andmeta-
bolic syndrome: a role for AT2R? – Several recent studies indi-
cate that ARBs may protect against the cognitive impairments
associated with vascular disease, AD, and other neurodegenera-
tive diseases (Mogi and Horiuchi, 2009). For example, pretreat-
ment with a non-hypotensive dose of telmisartan signiﬁcantly
inhibits the cognitive decline induced by intracerebroventricu-
lar (i.c.v.) injection of Aβ1–40, an experimental model of AD
(Tsukuda et al., 2007, 2009; Mogi et al., 2008), and also prevents
Aβ deposition in AD models (Mogi et al., 2006, 2007b, 2008;
Tsukuda et al., 2007, 2009). However, the link between AT2R
and cognitive defects is not yet clearly established. Figure 2 pro-
vides a general overview of the functional changes of AD and
how AT2R could help recover some of these changes.
• Type 2 diabetes mellitus (T2DM), hypertension and metabolic
syndrome (which is deﬁned as a cluster of obesity, high blood
pressure, hyperglycemia, and insulin resistance) are associated
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FIGURE 2 | Alzheimer’s disease: targets of functional disruptions and proposed protective functions associated with the activation of the AT2
receptor of angiotensin II.
with an increased risk of dementia (both AD and vascular
dementia) (Yaffe et al., 2004a,b; Biessels and Kappelle, 2005;
Qiu et al., 2005; Whitmer et al., 2005; Craft, 2006, 2009; Mogi
et al., 2006; de la Monte, 2009; Mogi and Horiuchi, 2009). In
T2DM patients, a major clinical study (Study on Cognition and
Prognosis in the Elderly, SCOPE; Lithell et al., 2003) and a clin-
ical double-blind study (Tedesco et al., 1999) have indicated
that ARBs have a further therapeutic effect on impaired cog-
nitive function beyond their antihypertensive effects compared
with other antihypertensive drugs. In this context, Tsukuda et
al. have demonstrated that candesartan improves the impaired
cognitive function induced by T2DM, with multiple beneﬁcial
effects (Tsukuda et al., 2007; Mogi et al., 2008).
LINKING SIGNALING AND FUNCTION: ALWAYS A DIFFICULT
CHALLENGE!
During the past 5 years, signiﬁcant progress has been achieved in
elucidating some of the puzzling elements of the AT2R-signaling
pathway proteins (Gendron et al., 2003a;Mogi andHoriuchi, 2009;
Porrello et al., 2009; Steckelings et al., 2010a; Figure 3). Some
of these elements may be linked to improvement of impaired
signaling functions as observed in AD:
• Ang II type 2 receptor may improve synaptic plasticity through
effects on ionic channel activity, sinceAT2R activation decreases
T-type calcium channel activity, increases K+ channel activity
(Kang et al., 1992, 1993; Buisson et al., 1995), and alters actin
cytoskeleton dynamics (Kilian et al., 2008).
• Ang II type 2 receptor activationmay supportmicrotubule orga-
nization and dynamics. Indeed, several studies have reported
that AT2R activates PP2A phosphatase (Huang et al., 1995,
1996a,2008; Kilian et al., 2008). PP2A is markedly deﬁcient in
AD, and responsible for a sustained increase in ERK1/ERK2,one
of the kinases involved in glycogen synthase kinase-3 (GSK-3)
inactivation. We have also shown that activity of Fyn, a src-
family kinase member, is required for AT2R-induced neurite
outgrowth (Guimond et al., 2010a). Since tau is a substrate
for both PP2A phosphatases, GSK-3 and Fyn, AT2R activation
may control the equilibrium between tau phosphorylation and
dephosphorylation (Hernandez and Avila, 2008; Hanger et al.,
2009; Hernández et al., 2010).
• Ang II type 2 receptor may also improve neurite architec-
ture, through effects on MAPs, as shown in neuronal cell lines
(Laﬂamme et al., 1996; Meffert et al., 1996; Côté et al., 1999; Li
et al., 2007a).
• Through methyl methanesulfonate sensitive 2 (MMS2; Mogi
et al., 2007a) and peroxisome proliferator-activated receptor
(PPARγ; Mogi et al., 2008), the AT2R improves cognitive func-
tion and the decrease in hippocampal neurogenesis observed
in amyloid-β-injection-induced cognitive decline (Mogi et al.,
2008) or in AT2R-deﬁcient mice (Mogi et al., 2007a; for review,
see Mogi and Horiuchi, 2009; Horiuchi et al., 2010).
• Ang II type 2 receptor activation may counteract vasoconstric-
tion, and favor vasodilation/vasorelaxation, through an increase
in nitric oxide (NO)–cGMPproduction and a decrease in super-
oxide production,NADPH oxidase superoxide production, and
NADPH oxidase (reviewed in Volpe et al., 2003; Widdop et al.,
2003; Steckelings et al., 2005).
• Ang II type 2 receptor activation by CGP42112 increases neu-
ronal survival and minimizes experimental post-stroke injury
(McCarthy et al., 2009), indicating that centrally administered
CGP42112 exhibits a neuroprotective effect. Such protective
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FIGURE 3 | Main signaling pathways for the AT2 receptor of angiotensin II in the brain.
effects may be consecutive to an increase in nitric oxide (NO)–
cGMP production and a decrease in superoxide production and
NADPH oxidase superoxide production and NADPH oxidase
(de la Torre, 2004; Iadecola et al., 2009) or to decreased inﬂam-
mation. Indeed, AT2R attenuates chemical hypoxia-induced
caspase-3 activation in primary cortical neuronal cultures
(Grammatopoulos et al., 2004). As recently reviewed (Rompe
et al., 2010; Stegbauer and Coffman, 2011), AT2R activation,
as in other inﬂammatory models, may decrease tumor necro-
sis factor-alpha (TNF-α) and NF-kB (nuclear factor kappa-
light-chain-enhancer of activated B cells) activity, resulting in
decreased production of interleukin 6 (IL-6). This effect is initi-
ated through increased activation of protein phosphatases and
increased synthesis of epoxyeicosatrienoic acid (Rompe et al.,
2010).
Nevertheless, certain contradictory studies suggest that AT2R
expression and conformation may change with age and may be
associated with some of the deleterious changes in AD (Kerr et al.,
2005; Abdalla et al., 2009). These conﬂicting hypotheses have been
difﬁcult to reconcile because of experimental limitations, partic-
ularly the lack of an orally active, selective ligand for the AT2R,
as discussed in the next section. Moreover, the earliest events
associated with activation of AT2R and the contribution of AT2R
signaling to cognitive decline remains unclear.
Other advances in the ﬁeld of AT2R signaling include the identi-
ﬁcation of direct intracellular partners, including the phosphatase
SHP-1 (Cui et al., 2001; Feng et al., 2002; Nouet et al., 2004; Mogi
et al., 2006; Li et al., 2007b), the transcription factor promyelo-
cytic zinc ﬁnger protein, PLZF (Senbonmatsu et al., 2003) and the
AT2 receptor-interacting protein (ATIP), also called AT2R bind-
ing protein of 50 kDa (ATBP50; Nouet et al., 2004; Wruck et al.,
2005; reviewed in Mogi et al., 2007a; Funke-Kaiser et al., 2010;
Rodrigues-Ferreira and Nahmias, 2010; see Figure 3 for a synop-
sis). Moreover, recent studies have identiﬁed intracellular crosstalk
pathways between the AT1R and the AT2R at the gene expression
level. Indeed,AT1R activation enhancesAT2RmRNAdegradation,
but AT2R activation increases AT2R mRNA transcription (Shibata
et al., 1997).
THE AT2R: PREVIOUS LIMITATIONS AND NEW
PERSPECTIVES
As previously mentioned, the identiﬁcation of AT2R-speciﬁc
actions has been hampered by the absence of appropriate selec-
tive ligands. Until recently, CGP42112A was the onlyAT2R agonist
available, but it also acted as an antagonist at high concentrations
(Dubey et al., 1998; Martineau et al., 1999; Ruiz-Ortega et al.,
2000; Fabiani et al., 2001). Furthermore, due to its peptidic nature,
CGP42112A could not be used readily in in vivo studies. Anders
Hallberg and colleagues, as recently summarized by Steckelings et
al. (2010a,b) and Unger and Dahlof (2010), have characterized the
properties of several non-peptidic compounds derived from the
prototypenon-selectiveAT1/AT2 receptor agonist L-162,313 (Wan
et al., 2004; Georgsson et al., 2005, 2006; Rosenstrom et al., 2005;
Wu et al., 2006; Murugaiah et al., 2007). One of these ligands, the
M24 compound (originally called C21; Wan et al., 2004; Georgs-
son et al., 2007), exhibits high afﬁnity for the AT2R (0.4 nM), but
very low afﬁnity for the AT1R (>10,000 nM) and acts as an AT2R
agonist (Wan et al., 2004).Using aneuronal/glioma cell line (a vari-
ant of NG108-15 cells expressing only the AT2R), we found that
C21/M24 stimulates neurite outgrowth through sustained activa-
tion of p42/p44mapk , as observed withAng II or CGP42112A (Wan
et al., 2004). In addition, C21/M24 also decreases cell proliferation
in NG108-15 cells, as does CGP42112A. In addition to our results,
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others have found thatC21/M24 loweredmean arterial bloodpres-
sure in hypertensive rats (Wan et al., 2004; Gelosa et al., 2009;
Bosnyak et al., 2010), improved ventricular function in a model
of rat myocardial infarction (Kaschina et al., 2009), and corrected
several intracellular perturbations and pro-inﬂammatory condi-
tions (Kaschina et al., 2009; Rompe et al., 2010). Thus, C21/M24
is the most selective AT2R agonist available to date and represents
a unique tool to delineate the speciﬁc roles of AT2R in different
cellular and animal models (Steckelings et al., 2010a; Unger and
Dahlof, 2010; recently reviewed in Steckelings et al., 2010b).
The next challenge is now to verify whether AT2R activation
by C21/M24 could rescue or improve cognitive performance. To
answer this question, we have induced learning deﬁciency by a
2-week treatment with intracerebral injection of amyloid-β (Aβ).
Key ﬁndings from our preliminary experiments are that selective
AT2R activation by C21/M24 attenuates the learning disturbance
in the Y-maze and water-maze tasks more efﬁciently than AT1R
blockade by losartan (Guimond et al., 2010b and unpublished
results). It is indeed well documented that Aβ treatment signif-
icantly induces a signiﬁcant learning disturbance in the Y-maze
and water-maze tasks, in addition to resulting in moderate neu-
ronal loss and promoting amyloid deposition in the cortex and
hippocampus (Yamaguchi and Kawashima, 2001; Tajima et al.,
2005; Mogi et al., 2006, 2008; Liu et al., 2009; Klyubin et al., 2011;
Srivareerat et al., 2011).
From the previous results demonstrating that AT2R stimula-
tion modulates phosphorylation of MAPs, including MAP2 and
MAP1B or tau, as well as modulates interactions between MAPs
and microtubules (Laﬂamme et al., 1996; Meffert et al., 1996; Côté
et al., 1999; Li et al., 2007b), it appears therefore that elucidating
the signaling mechanisms linking AT2R activation and cytoskele-
tal remodeling is key to understanding the cognitive roles of the
AT2R in hippocampal neurons.
Based on the current paradigms of AT1R/AT2R function,
one aspect of AT1R/AT2R regulation is particularly intrigu-
ing. Could the age-related shift in the relative expression of
the AT1R and AT2R, in which AT1R expression increases
and AT2R expression decreases, explain some cellular aspects
of aging, especially those relating to altered cell number
(von Bohlen und Halbach et al., 2001)?
CONCLUSION – RELEVANCE TO ALZHEIMER’S DISEASE AND
RELATED DEMENTIAS
Poor cognitive performance in AD signiﬁcantly impairs social
interaction and the quality of life of patients. Therefore any treat-
ment aimed at improving cognitive functions is likely to slowdown
symptoms and improve quality of life. An estimated 33 million
elderly persons worldwide suffer from dementia, and this number
is expected to reach 81.1 million by 2040 (Ferri et al., 2005; Source:
Rising Tide: the Impact of Dementia on Canadian Society, a report
of the Alzheimer’s Society of Canada). Life style-related disorders,
such as hypertension,diabetesmellitus, and obesity havemoreover
been implicated as risk factors for dementia (Yaffe et al., 2004a,b;
Biessels and Kappelle, 2005; Qiu et al., 2005; Whitmer et al., 2005;
Craft, 2006, 2009; Mogi et al., 2006; de la Monte, 2009; Mogi and
Horiuchi, 2009).
As described in the previous sections, AT2R activation may act
at several locations in the cascade of alterations leading to cog-
nitive impairment and neuronal dysfunction observed in AD. In
particular, AT2R may act not only at the neuronal level, but also
on vasculature and on inﬂammation associated with Alzheimer’s.
As outlined in this review, an increasing number of studies suggest
that the protective effects of angiotensin II (AT1) receptor block-
ers on brain damage and cognition may result not only from the
inhibition of AT1R effects, but also from the beneﬁcial effect due
to unopposed activation of AT2R. In addition, the relationship
between impaired energy metabolism/obesity/insulin resistance
and the increased risk of dementia (both AD and vascular demen-
tia; Yaffe et al., 2004a,b; Qiu et al., 2005; Whitmer et al., 2005;
Mogi and Horiuchi, 2009) emphasizes that all the mechanisms by
which AT2R acts may have a beneﬁcial protective effect. If further
research conﬁrms the promising early results, the neuroprotec-
tive effect of central AT2R stimulation with the recently developed
C21/M24, a non-peptide, selective AT2R agonist, may thus repre-
sent a new pharmacological tool in AD and others neurological
cognitive disorders. In addition, unraveling the underlying effects
of the AT2R on neuronal plasticity may lead to the development
of even more selective therapies.
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